Intercept shares should be bought amid biotech weakness, says Oppenheimer After meeting with Intercept's management, Oppenheimer believes that the company's management successfully explained issues involving OCA lipids, and the firm is now more confident in the company's ability to deal with future regulatory uncertainties. Oppenheimer keeps an Outperform rating on the stock.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Intercept feedback positive, says BofA/Merrill BofA/Merrill's recent discussions with NASH liver expert believes Intercept's OCA path to market may be straight forward and not require CV outcomes data prior to approval and that FLINT study will have a positive impact on the NASH resolution. The firm reiterates its Buy rating and $872 price target.